Lung cancer drug shows promise against brain metastases

NCT ID NCT04563871

Completed Disease control Sponsor: Sehhoon Park Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jul 29, 2026 · Updated 3 times

Summary

This study tested the drug osimertinib (Tagrisso) in 73 patients with a specific type of lung cancer that had spread to the lining of the brain and spinal cord (leptomeningeal metastases). Patients took one 80 mg tablet daily. The goal was to see if the drug could improve overall survival and control the spread of cancer in this hard-to-treat area.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Osimertinib (Tagrisso) 80 mg tablet taken once daily
What this could lead to: If successful, this could provide an effective treatment option for lung cancer patients whose disease has spread to the brain and spinal cord lining, potentially extending survival.
What could go wrong: This is a single-arm Phase II study with no comparison group, so results may be less definitive. The drug may not work for all patients and side effects are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LEPTOMENINGEAL METASTASES ASSOCIATED WITH EGFR MUTATION-POSITIVE NON-SMALL CELL LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

neoplastic meningitis non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NON-SMALL CELL LUNG CANCER (NSCLC)

Contacts and locations

Locations

Asan Medical Center

Seoul, South Korea
ChungBuk National University Hospital

Cheonju, South Korea
National Cancer Center

Goyang, South Korea
Samsung Medical Center

Seoul, 135-710, South Korea
Seoul National University Bundang Hospital

Seongnam, South Korea
Seoul National University Hospital

Seoul, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.